{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kronzer VL"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","NIA NIH HHS","National Institute on Aging"],"pagination":["348-355"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8934743"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["75(2)"],"pubmed_abstract":["<h4>Objective</h4>We aimed to determine the population-based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria.<h4>Methods</h4>This population-based cohort study included incident DM from January 1, 1995 to December 31, 2019. We manually reviewed all individuals with at least 1 code for DM or polymyositis to determine if they met EULAR/ACR criteria, subspecialty physician diagnosis, and/or Bohan and Peter criteria. We age- and sex-adjusted incidence and prevalence estimates to the US non-Hispanic White year 2000 population and estimated prevalence on January 1, 2015. Standardized mortality ratios (SMRs) with 95% confidence intervals (95% CIs) compared observed to expe"],"journal":["Arthritis care & research"],"pubmed_title":["Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study."],"pmcid":["PMC8934743"],"funding_grant_id":["UL1 TR002377","R33 AG058738","R01AG034676","R01 AG034676"],"pubmed_authors":["Crowson CS","Davis JM","Kronzer VL","Kimbrough BA","Holmqvist M","Ernste FC"],"additional_accession":[]},"is_claimable":false,"name":"Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study.","description":"<h4>Objective</h4>We aimed to determine the population-based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria.<h4>Methods</h4>This population-based cohort study included incident DM from January 1, 1995 to December 31, 2019. We manually reviewed all individuals with at least 1 code for DM or polymyositis to determine if they met EULAR/ACR criteria, subspecialty physician diagnosis, and/or Bohan and Peter criteria. We age- and sex-adjusted incidence and prevalence estimates to the US non-Hispanic White year 2000 population and estimated prevalence on January 1, 2015. Standardized mortality ratios (SMRs) with 95% confidence intervals (95% CIs) compared observed to expe","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-05-29T21:29:46.456Z","creation":"2025-05-29T21:29:46.456Z"},"accession":"S-EPMC8934743","cross_references":{"pubmed":["34549549"],"doi":["10.1002/acr.24786"]}}